• Species Reactivity

  Human

• Specificity

  Detects human IL-22BP in direct ELISAs. In direct ELISAs, no cross-reactivity with mouse IL-22BP is observed.    
   

• Source

  Monoclonal Mouse IgG    _2B Clone # 875504

• Purification

  Protein A or G purified from hybridoma culture supernatant

• Immunogen

  Mouse myeloma cell line NS0-derived recombinant human IL-22BP    
  Thr22-Pro263    
  Accession # Q969J5

• Formulation

  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.

• Label

  Unconjugated

Applications

• Recommended    
  Concentration

  Sample

• CyTOF-ready

  Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

• 
  

• Intracellular Staining by Flow Cytometry

  2.5 µg/10    ⁶ cells

  See below

• 
  

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Data Examples

Preparation and Storage

• Reconstitution

  Reconstitute at 0.5 mg/mL in sterile PBS.

• Shipping

  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

• Stability & Storage

  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.    

• 12 months from date of receipt, -20 to -70 °C as supplied.

• 1 month, 2 to 8 °C under sterile conditions after reconstitution.

• 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IL-22BP

Interleukin 22 Binding Protein (IL-22BP), also known as Cytokine Receptor Family (CRF) 2‑10, CRF2-X, and IL-22 RA2, is a secreted glycoprotein belonging to the type II cytokine receptor family. It encodes a precursor protein of 231 amino acid (aa) residues with a 21 aa putative signal peptide and five potential N-linked glycosylation sites. IL-22BP lacks a transmembrane and cytoplasmic domain and is most closely related to the extracellular domains of IL‑22 R (CRF2-9) and IL-20 R (CRF2-8), sharing 33% and 34% aa sequence identity, respectively. It also shares sequence homology with the extracellular domains of IL-10 R (29%), IL-10 R beta (30%), the IFN receptors (23‑25%) and tissue factor (26%). IL-22BP antagonizes IL-22 activity by specifically binding IL-22 with high affinity and blocking its interaction with the cell surface IL-22 receptor heteromeric complex composed IL-22 R and IL‑20 R. IL-22BP is expressed in multiple tissues. The highest levels of expression are found in breast, lungs and colon. The major cell types producing IL-22BP are monocytes, activated B cells and epithelial cells (1), and is constitutively expressed by a subset of conventional dendritic cells (2). IL-22BP is regulated by the inflammasome and it has been suggested to modulate tumorigenesis in the intestine (3).

• References:

1. Xu, W. et al. (2001) Proc. Natl. Acad. Sci. USA 98:9511.

2. Martin, J. et al. (2014)  Mucosal Immunol. 7:101.

3. Huber, S. et al. (2012)  Nature 491:259.

• Long Name:

  Interleukin 22 Binding Protein

• Entrez Gene IDs:

  116379 (Human); 237310 (Mouse)

• Alternate Names:

  class II cytokine receptor; CRF2-10; CRF2-S1IL22BP; CRF2-X; Cytokine receptor class-II member 10; Cytokine receptor family 2 member 10; Cytokine receptor family type 2, soluble 1; IL-22 RA2; IL-22 receptor subunit alpha-2; IL22BP; IL-22BP; IL-22BPCRF2X; IL22RA2; IL-22RA2; IL-22R-alpha-2; interleukin 22 receptor, alpha 2; interleukin 22-binding protein; interleukin-22 receptor subunit alpha-2; Interleukin-22-binding protein; MGC150509; MGC150510; zcytoR16